UPDATE 1-Galenica to buy biotech firm Relypsa for $1.5 bln before break-up

July 21 (Reuters) - Galenica has agreed to buy U.S. biotech firm Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.